Acuta Capital Partners’s Praxis Precision Medicines PRAX Stock Holding History

Acuta Capital Partners’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$27.4M	Buy	84,901 +1,865	+2%	+$577K	19.3%	1
2025 Q4	$24.5M	Buy	83,036 +33,285	+67%	+$6.2M	16.62%	2
2025 Q3	$2.64M	Sell	49,751 -24,336	-33%	-$1.18M	2.72%	12
2025 Q2	$3.12M	Sell	74,087 -13,054	-15%	-$497K	4.35%	9
2025 Q1	$3.3M	Buy	87,141 +19,641	+29%	+$1.23M	3.83%	10
2024 Q4	$5.19M	Buy	67,500 +10,000	+17%	+$724K	5.23%	7
2024 Q3	$3.31M	Sell	57,500 -106,931	-65%	-$5.78M	2.68%	15
2024 Q2	$6.8M	Buy	164,431 +2,129	+1%	+$101K	5.73%	5
2024 Q1	$9.9M	Sell	162,302 -137,334	-46%	-$6.16M	6.43%	2
2023 Q4	$6.68M	Buy	299,636 +636	+0.2%	+$11.5K	3.76%	8
2023 Q3	$7.67M	Buy	299,000 +15,667	+6%	+$296K	5.14%	4
2023 Q2	$4.89M	Buy	+283,333	New	+$4.34M	3.31%	12
2021 Q2	–	Sell	-10,282	Closed	-$5.05M	–	47
2021 Q1	$5.05M	Buy	10,282 +5,239	+104%	+$3.73M	1.82%	25
2020 Q4	$4.16M	Buy	+5,043	New	+$2.94M	1.13%	32

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Acuta Capital Partners's PRAX Position: Q1 2026 in Review

Acuta Capital Partners increased its Praxis Precision Medicines (PRAX) stake by 2.2% in Q1 2026, buying an estimated $577K and bringing the position to 84,901 shares worth $27.4M. The position accounts for 19.3% of the portfolio, ranked #1.

Acuta Capital Partners first reported a position in PRAX in Q4 2020 and has held it in 14 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

Acuta Capital Partners held 84,901 shares of Praxis Precision Medicines worth $27.4M as of Q1 2026.
Acuta Capital Partners bought 1,865 Praxis Precision Medicines shares in Q1 2026, an estimated $577K.
Praxis Precision Medicines made up 19.3% of Acuta Capital Partners's portfolio in Q1 2026, its #1 holding.
Acuta Capital Partners first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 14 quarters since.
289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.